The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a greater substantial loss in body size and benefit metabolic markers,… Read More